Prolonged progression-free survival on epidermal growth factor receptor-tyrosine kinase inhibitors predicts superior response to atezolizumab-based therapy over chemotherapy in epidermal growth factor receptor-mutated non-small-cell lung cancer following progression

Prolonged progression-free survival on epidermal growth factor receptor-tyrosine kinase inhibitors predicts superior response to atezolizumab-based therapy over chemotherapy in epidermal growth factor receptor-mutated non-small-cell lung cancer following progression

Background: Patients with non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations who experience disease progression after treatment with an EGFR-tyrosine kinase inhibitor (EGFR-TKI) often receive subsequent treatment with either platinum-based chemotherapy (Ch...

Full description

Saved in:
Bibliographic Details
Main Authors: K. Morimoto, T. Yamada, N. Furuya, H. Tanaka, A. Yoshimura, T. Oba, M. Hibino, T. Fukuda, Y. Goto, A. Nakao, S. Ogusu, Y. Okazaki, T. Harada, T. Ota, K. Masubuchi, K. Mikami, T. Hata, S. Matsumoto, R. Honda, K. Date, Y. Chihara, K. Takayama
Format: Article
Language:English
Published: Elsevier 2025-06-01
Series:ESMO Real World Data and Digital Oncology
Subjects:
non-small-cell lung cancer
EGFR mutation
immune checkpoint inhibitor
atezolizumab
Online Access:http://www.sciencedirect.com/science/article/pii/S2949820125000414
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items